Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 13/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 12/20 | 0.54 |
| ▸ | CCR3 | P51677 | 1/20 | 0.52 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.52 |
| ▸ | DRD2 | P14416 | 4/20 | 0.50 |
| ▸ | DRD4 | P21917 | 4/20 | 0.50 |
| ▸ | DRD3 | P35462 | 4/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3249080 | 0.82 | GBA1 (0.49) | — | |
| SCHEMBL4207989 | 0.82 | CHRM3 (0.60) | CHRM3CHRM2OPRL1DRD2DRD4 | |
| SCHEMBL13945986 | 0.82 | CHRM3 (0.60) | CHRM3CHRM2OPRL1DRD2DRD4 | |
| SCHEMBL13945982 | 0.79 | OPRL1 (0.61) | CHRM3CHRM2OPRL1DRD2DRD4 | |
| SCHEMBL13945985 | 0.79 | OPRL1 (0.61) | CHRM3CHRM2OPRL1DRD2DRD4 | |
| SCHEMBL13945988 | 0.76 | CHRM2 (0.57) | CHRM3CHRM2OPRL1DRD2DRD4 | |
| SCHEMBL3063295 | 0.75 | CHRM3 (0.59) | CHRM3CHRM2OPRL1DRD2DRD4 | |
| SCHEMBL13986105 | 0.74 | HPGD (0.46) | CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL31437068 | 0.74 | CHRM3 (0.61) | CHRM3CHRM2OPRL1DRD2DRD4 | |
| SCHEMBL3262861 | 0.74 | CHRM3 (0.54) | CHRM3CHRM2CCR3OPRL1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1856100-B1 | CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2010-05-05 | — | — | EP | disclosed |
| US-7632832-B2 | CGRP receptor antagonists | MERCK & CO., INC. (US) | 2009-12-15 | — | — | US | disclosed |
| US-20080125413-A1 | Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125413-A1 | Cgrp Receptor Antagonists | CALCRL, NPY1R, CCKBR | CHRM3 227/4885CHRM2 177/4885CCR3 599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.